Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage…
Month: August 2023
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage…
Digipath Announces Record Earnings of $292,533 for Recent Quarter Ended June 30
Digipath, Inc. High capacity LCMS-QQQ for testing pesticides Lab Operations has Seen a Consistent Uptick…
Digipath Announces Record Earnings of $292,533 for Recent Quarter Ended June 30
Digipath, Inc. High capacity LCMS-QQQ for testing pesticides Lab Operations has Seen a Consistent Uptick…
Evaxion announces Executive Management Changes to strengthen the AI-strategy
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
Evaxion announces Executive Management Changes to strengthen the AI-strategy
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting…
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting…
Vaxxinity to Present at Upcoming Investor Conferences in September
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S….
Vaxxinity to Present at Upcoming Investor Conferences in September
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S….
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Independent Safety Committee approves next cohort dosing of RECCE® 327 (R327) at two faster infusion…
Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Independent Safety Committee approves next cohort dosing of RECCE® 327 (R327) at two faster infusion…
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”)…
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”)…
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with…
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with…
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
MIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
MIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…